Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
PHARMADRUG ADVANCES PRODUCT AND CLINICAL DEVELOPMENT OF CEPHARANTHINE TO TREAT RARE CANCERS AND INFECTIOUS DISEASES Toronto, Ontario--(Newsfile Corp. - April 20, 2021...
PHARMADRUG INITIATES DMT RESEARCH ACTIVITIES VIA COLLABORATION WITH THE UNIVERSITY OF MICHIGAN FOR FOUNDATIONAL DMT RESEARCH STUDY Toronto, Ontario, Canada...
PHARMADRUG FILES FOR FDA ORPHAN DRUG DESIGNATION FOR DMT IN KIDNEY TRANSPLANTATION AND EXPANDS ON ITS PSYCHEDELICS STRATEGY Toronto, Ontario--(Newsfile Corp. - February 25, 2021) - PharmaDrug...
PHARMADRUG FILES FOR FDA ORPHAN DRUG DESIGNATION FOR DMT IN STROKE Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the...
PHARMADRUG APPOINTS WORLD-RENOWNED DMT EXPERT DR. STEVEN A. BARKER TO ITS SCIENTIFIC ADVISORY BOARD FOR PSYCHEDELIC PHARMACEUTICALS Toronto, Ontario...
PHARMADRUG SIGNS SUPPLY AGREEMENT WITH GLOBAL CANNABIS SUPPLIER AND Provides update on german operations and balance sheet improvements Toronto, Ontario-- February 4, 2021 -- InvestorsHub...
PHARMADRUG COMPLETES ACQUISITION OF SAIRIYO THERAPEUTICS INC. Toronto, Ontario -- February 2, 2021 -- InvestorsHub NewsWire - PharmaDrug Inc. (CSE: BUZZ) (OTC:...
PHARMADRUG ENTERS DEFINITIVE AGREEMENT FOR ACQUISITION OF SAIRIYO THERAPEUTICS INC. WHO RECENTLY RECEIVED ORPHAN DRUG DESIGNATION FROM FDA FOR ESOPHAGEAL CANCER Toronto, Ontario...
PHARMADRUG ANNOUNCES LOI TO ACQUIRE SAIRIYO THERAPEUTICS INC. Toronto, Ontario -- January 12, 2021 -- InvestorsHub NewsWire -- PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF...
TORONTO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Aura Health Inc. (the “Company” or “Aura”) (CSE:BUZZ, OTCQB:LMLLF) is pleased to provide an operational update on Pharmadrug Production GmbH (the...
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
| 4 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
| 156 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
| 260 | 0.035 | 140 | 0.025 | 0.205 | 0.01 | 886672 | 0.0906725 | CS |
| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
